Androgenetic Alopecia Pipeline Insight 2023 (Updated), NDA Approvals | Kerastem, Addpharma, Cutia Therapeutics, Biosplice Therapeutics, Aclaris Therapeutics, Kintor Pharmaceutical, Dong-A ST Co., Ltd., Cassiopea

DelveInsight's, "Androgenetic Alopecia Pipeline Insight 2023" report provides comprehensive insights about 12+ companies and 12+ pipeline drugs in the Androgenetic Alopecia pipeline landscape. It covers the Androgenetic Alopecia pipeline drug profiles, including Androgenetic Alopecia clinical trials and nonclinical stage products. It also covers the Androgenetic Alopecia therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

To explore more information on the latest breakthroughs in the Androgenetic Alopecia Pipeline treatment landscape of the report, click here @ Androgenetic Alopecia Pipeline Outlook- https://www.delveinsight.com/report-store/androgenetic-alopecia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key Takeaways from the Androgenetic Alopecia Pipeline Report
• DelveInsight's Androgenetic Alopecia Pipeline report depicts a robust space with 12+ active players working to develop 12+ pipeline therapies for Androgenetic Alopecia.
• The leading Androgenetic Alopecia Companies include Kerastem, Addpharma, Cutia Therapeutics, Biosplice Therapeutics, Aclaris Therapeutics, Kintor Pharmaceutical, Dong-A ST Co., Ltd., Cassiopea, Follica, Applied Biology Inc., AndroScience Corporation, AnnJi Pharmaceutical, Carmell Therapeutics, and others
• Promising Androgenetic Alopecia Pipeline Therapies include 5% Minoxidil Topical Foam, Vehicle Topical Foam, AD-208, Minoxidil, REVIAN 101, Topical SM04554 solution, Dutasteride, and others
• OLX72021, a treatment for androgenic alopecia, also known as male-pattern baldness, has been approved for use in a Phase 1 clinical trial by the Human Research Ethics Committee (HREC) in Australia, according to OliX Pharmaceuticals, Inc. (KOSDAQ: 226950), a leading provider of RNAi therapeutics.
• The American Academy of Dermatology Association's 2023 Annual Meeting (AAD 2023) took place in New Orleans, Louisiana, USA, from March 17-21, 2023. Dermatologists from around the world shared the newest developments in dermatology research at one of the biggest, most prominent, and most representative dermatologic societies. The self-developed topical drug candidates pyrilutamide (KX-826) and GT20029 from Kintor Pharmaceutical Limited ("Kintor Pharma," HKEX: 9939) have garnered a lot of interest at the meeting, showcasing the company's innovative capabilities and the therapeutic potential of its androgenetic alopecia (AGA) and acne pipelines.

For further information, refer to the detailed Androgenetic Alopecia Unmet Needs, Androgenetic Alopecia Market Drivers, and Androgenetic Alopecia Market Barriers, click here for Androgenetic Alopecia Ongoing Clinical Trial Analysis- https://www.delveinsight.com/sample-request/androgenetic-alopecia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Androgenetic Alopecia Overview
Androgenetic alopecia is a common form of hair loss in both men and women. In men, this condition is also known as male-pattern baldness. Hair is lost in a well-defined pattern, beginning above both temples. Over time, the hairline recedes to form a characteristic ""M"" shape. Pattern or androgenetic alopecia is a genetically predetermined disorder due to excessive response to androgens which affects up to 50% of males and females.

Request a sample and discover the recent advances in Androgenetic Alopecia Ongoing Clinical Trial Analysis and Medications, click here @ Androgenetic Alopecia Treatment Landscape- https://www.delveinsight.com/sample-request/androgenetic-alopecia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Androgenetic Alopecia Emerging Drugs

• KX-826: Kintor Pharma
KX-826 is an androgen receptor (AR) antagonist and a potential first-in-class topical drug for the treatment of AGA and acne vulgaris. For the AGA indication, on 8 September 2021, Kintor Pharma announced that the primary endpoint of the phase II clinical trial of KX-826 on adult male patients was met, as results showed good efficacy and safety profile. On 11 July 2021, Kintor Pharma announced that the Food and Drug Administration of the United States greenlighted KX-826's phase II clinical trial for AGA to be conducted in the United States.

• Clascoterone: Cassiopea
Clascoterone solution 7.5% is a novel AR inhibitor that targets androgen receptors in the scalp and is currently being studied for the treatment of androgenetic alopecia (AGA). Clascoterone solution 7.5% acts by inhibiting DHT's binding with androgen receptors in scalp hair follicles and thus may interfere with DHT's effect on scalp hair loss. A Phase II dose ranging study with clascoterone solution in males ended in early 2019. Clascoterone solution 7.5% was selected as the best candidate for the Phase III adult male AGA program. A Phase II study involving female AGA subjects is underway with top-line results expected 3Q 2021.

Dive deep into rich insights for drugs for Androgenetic Alopecia Market Drivers and Androgenetic Alopecia Market Barriers, click here @ Androgenetic Alopecia Unmet Needs and Analyst Views- https://www.delveinsight.com/sample-request/androgenetic-alopecia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Androgenetic Alopecia Pipeline Therapeutics Assessment
There are approx. 12+ Androgenetic Alopecia companies which are developing the Androgenetic Alopecia therapies. The Androgenetic Alopecia companies which have their Androgenetic Alopecia drug candidates in the most advanced stage, i.e. Phase II include, Kintor Pharma.

Androgenetic Alopecia Pipeline Segmentation
Phases
DelveInsight's Androgenetic Alopecia pipeline report covers around 12+ products under different phases of clinical development like
• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Androgenetic Alopecia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical.
• Molecule Type

Androgenetic Alopecia Products have been categorized under various Molecule types such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Androgenetic Alopecia Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Scope of the Androgenetic Alopecia Pipeline Report
• Coverage- Global
• Androgenetic Alopecia Companies- Kerastem, Addpharma, Cutia Therapeutics, Biosplice Therapeutics, Aclaris Therapeutics, Kintor Pharmaceutical, Dong-A ST Co., Ltd., Cassiopea, Follica, Applied Biology Inc., AndroScience Corporation, AnnJi Pharmaceutical, Carmell Therapeutics, and others
• Androgenetic Alopecia Pipeline Therapies- 5% Minoxidil Topical Foam, Vehicle Topical Foam, AD-208, Minoxidil, REVIAN 101, Topical SM04554 solution, Dutasteride, and others
• Androgenetic Alopecia Pipeline Segmentation: Product Type, Molecule Type, Route of Administration

Got Queries? Find out the related information on Androgenetic Alopecia Mergers and acquisitions, Androgenetic Alopecia Licensing Activities @ Androgenetic Alopecia Emerging Drugs, and Recent Trends- https://www.delveinsight.com/sample-request/androgenetic-alopecia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Introduction
2. Executive Summary
3. Androgenetic Alopecia: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Late Stage Products (Phase III)
7. Drug Name: Company Name
8. Drug profiles in the detailed report…..
9. Mid Stage Products (Phase II)
10. KX-826: Kintor Pharma
11. Drug profiles in the detailed report…..
12. Early stage products (Phase I)
13. GT20029: Kintor Pharmaceuticals
14. Drug profiles in the detailed report…..
15. Inactive Products
16. Androgenetic Alopecia Key Companies
17. Androgenetic Alopecia Key Products
18. Androgenetic Alopecia- Unmet Needs
19. Androgenetic Alopecia- Market Drivers and Barriers
20. Androgenetic Alopecia- Future Perspectives and Conclusion
21. Androgenetic Alopecia Analyst Views
22. Androgenetic Alopecia Key Companies
23. Appendix

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 9193216187
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting-services

This release was published on openPR.